
According to Benzinga Pro data, during Q1, bluebird bio (NASDAQ:BLUE) posted sales of $1.95 million. Earnings were up 21.22%, but bluebird bio still reported an overall loss of $122.15 million. bluebird bio collected $1.61 million in revenue during Q4, but reported earnings showed a $155.05 million loss.